World Courier - Savsu Global Alliance!

world courier logo.png
London, UK and Albuquerque, NM (January 23, 2018) - World Courier, the global leader in specialty logistics and a part of AmerisourceBergen, today announced the availability of SAVSU Technologies’ smart precision shipping containers throughout its network. SAVSU designs and manufactures innovative high-performance cloud-connected passive storage and transport containers optimized for the cell and gene therapy supply chain.

The combination of World Courier’s global logistics network and SAVSU’s patent pending, enhanced temperature-controlled evo DV4 & DV10 liquid nitrogen (LN2) shippers will enable cell and gene therapy developers to more efficiently and effectively move critical biologic shipments at cryogenic temperatures worldwide, with enhanced visibility and shipment monitoring capabilities.

Very excited to announce the beginning of a collaborative program with World Courier.  World is a terrific company with a global footprint.   Our evo product will be distributed globally within their network for use by their cell and gene therapy customers.   Amongst other services, World will be able to rapidly dispatch our DV10 and DV4 units to customers.

If you have an interest in the evo system, you can now contact World's sales and technical team in one of their 140 offices worldwide.

Full announcement here

More Patents For Savsu!


It is gratifying every time we are granted a patent on our technology.   We have filed a lot of them and more are coming in 2018 (yeah we are working on some really cool new stuff).

Looking at our growing portfolio of patents,  reminds me of how far we have come on this journey of building the evo Cold Chain 2.0 System.   It also reminds me that we do not pursue new technology in this field just for the thrill of accumulating IP.   We pursue new technology because we have a vision and the old cold chain technology has hit a dead end.  With the old tech it was a case of "you can't get there from matter how hard you try".   A radically different approach was required to solve the problem of safely transporting the new cell and gene therapies that are now emerging.   Our vision was for a technically sophisticated system that was easy to use and could scale effortlessly to commercial levels.   Turns out that when we started to build that system, we quickly realized that we were on our own and we would, in the ensuing years,  end up inventing a whole lot of new parts.    That is where the IP comes from...inventing as we go to realize our vision.


SAVSU Technologies and BioLife Solutions Increase evo® Intellectual Property Estate with Notice of Allowance of New Patent for Cold Chain Technologies

13 Additional Pending Patent Applications Submitted for evo Smart Shippers, Liquid Nitrogen Dry Vapor Shippers (DVS) and Cold Chain SaaS Application

06:30 ET from  BioLife Solutions, Inc.

BOTHELL, Wash. and ALBUQUERQUE, N.M., Jan. 18, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and SAVSU Technologies, the leading developer of smart, precision biologic shipping containers and cloud-based cold chain management SaaS solutions, today announced that the USPTO has issued a notice of allowance of a patent application titled "Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature Sensitive Biologic Based Materials". The inventors are Bruce McCormick, President of SAVSU Technologies, and Mike Rice, CEO of BioLife Solutions.

Since the formation of the BioLife Solutions – SAVSU Technologies biologistex™ joint venture in the fourth quarter of 2014, the companies have submitted 13 other patent applications related to novel innovations incorporated into current, or to be incorporated into future, precision thermal shipping containers under the evo brand. This includes models that precisely maintain biologic payload temperature stability across the entire shipping continuum; including -196°C liquid nitrogen dry vapor shippers, -80°C dry ice shippers, and 2° - 8°C and controlled room temperature (CRT) shippers using conditioned phase change insulating materials. These patent applications also include claims related to the Cold Chain Software as a Service (SaaS) live cell visibility platform.

Bruce McCormick commented, "We are pleased to receive this notice of allowance of what we believe will be a series of granted patent applications we filed to protect our growing intellectual property estate. We believe our hardware and software innovations, embodied in current and future evo models, will offer significant value to the growing regenerative and personalized medicine markets."

Mike Rice, BioLife CEO, remarked, "This notice of allowance is another validation of the vision SAVSU and BioLife formed several years ago, with a focused and intentional goal to improve cold chain logistics of cell and gene therapies. We believe the advanced and innovative evo hardware and software technologies will have tremendous impact on the preservation, delivery, and quality management of these precious, time and temperature sensitive biologic medicines." 


SAVSU is a leading designer and manufacturer of innovative high-performance cloud-connected passive storage and transport containers for temperature sensitive biologics and pharmaceuticals. Our mission is to improve global health by greatly reducing the waste and risks associated with the improper freezing and overheating of thermal-sensitive medicines and biologics. SAVSU has developed proprietary state-of-the-art technology to ultimately lower costs and improve delivery of these most essential materials. For more information please visit

About BioLife Solutions

BioLife Solutions is the leading developer, manufacturer and supplier of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media for cells and tissues. Our proprietary HypoThermosol® and CryoStor® platform of biopreservation media products are highly valued in the regenerative medicine, biobanking and drug discovery markets. These are serum-free, protein-free, fully defined, and formulated to reduce preservation-induced cell damage and death. Our enabling, embeddable technologies provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. 

For more information please visit, and follow BioLife on Twitter.

Cautions Regarding Forward Looking Statements

Except for historical information contained herein, this press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements concerning the company's anticipated business and operations, the potential utility of and market for its products and services, potential revenue growth and market expansion, commercial manufacturing of our customers' products, and projected financial results. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of products; uncertainty regarding third party market projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

BioLife Solutions, Inc. 

Media & Investor Relations


Media & Investor Relations

Roderick de Greef

Dana Barnard

Chief Financial Officer

Chief Executive Officer

(425) 686-6003 

(505) 603-5306



SOURCE BioLife Solutions, Inc.



See You At Cell and Gene Therapy: January 22-25 in Miami!


We are very excited to be exhibiting at Cell and Gene Therapy 2018 in Miami, January 22-25.   Last year's event was terrific.   The venue is the Hyatt Regency - Miami (location here).  This year Savsu will be exhibiting in the unique "Supply Chain & Logistics Hub".  We will be in the hub with seven key cell and gene therapy service suppliers:



World Courier 

Brooks Life Science Systems


Fisher BioServices

You can book a 30 minute tour that exposes you to the full cell and gene therapy supply chain.  From the Cell and Gene Therapy website:   "Take a journey through a cell & gene therapy supply chain of the future! Demystify every component, from cryopreservation to product tracking, and from initial sample collection to clinical site administration. You will leave with a clear vision of what YOUR product’s optimal supply chain management model should look like through scale up to the commercial setting."

Please stop by and learn about our evo® Cold Chain 2.0 System and get a demonstration of our new evo DV4 and DV10, revolutionary dry vapor shippers.   To reserve meeting time with us, please email us here.  If you would like to book a complete tour through the supply chain, you can do that on the Cell and Gene Therapy website,  here

See you in Miami!




Second ‘don’t eat me’ signal found on cancer cells

weissman stanford.jpg

Fascinating and important article on finding a second "don't eat me signal" that certain cancers use to protect themselves.   Article about Irving Weissman and his team's work at Stanford can be read here.

"... aggressive cancers express a ‘don’t eat me’ signal in the form of CD47 on their surfaces. Now we’ve identified a second ‘don’t eat me’ signal and its complementary receptor on macrophages. We’ve also shown that we can overcome this signal with specific antibodies and restore the ability of macrophages to kill the cancer cells.”

Irving Weissman, Stanford University School of Medicine

stanford logo.jpg

3 keys to scale-up CAR T-Cell therapy manufacturing

pa consulting.jpg

Good article on the challenges of scaling up CAR T Cell therapy manufacturing in BioProcess Online by Perry Yin from PA Consulting.  We agree with points made regarding logistics and designed the evo® Cold Chain 2.0 system to meet these new challenges.   You can read the article here.

1. Optimize the Manufacturing Process Through Automation

2. Coordinate Logistics With Real-Time Tracking And Feedback

"Given how personalized CAR T-cell therapy is, the patient is an integral component of the supply chain. It is critical that the cellular material taken and produced from one patient is only used to treat that specific patient and that the entire process is completed as quickly as possible. The logistics involved in getting the cells out of the patient to the manufacturing facility and then back into the right patient require complex logistical coordination, involving significantly higher levels of tracking than other cold-chain products that are not as patient-specific and time-sensitive."

3. Move Toward A Decentralized Manufacturing Model



evo® Smart Shipper Embedded in 8 Trials Using Treg Cells for Diabetes, Lupus, Pemphigus, and Organ Transplantation

ucsf logo.jpg

UCSF selects evo® Smart Shipper for clinical Treg Cell trials 

Critical Phase 1 research to advance treatment for autoimmune, cardiovascular, neurological diseases

Savsu Technologies is pleased to announce that our evo® Cold Chain 2.0 System has been selected for eight active and pending clinical trials at the University of California, San Francisco (UCSF) Diabetes Center and Department of Surgery. Savsu’s evo system will be used in conjunction with BioLife's hypothermic storage and cryopreservation freeze media in the important Phase 1 trials investigating effective cold chain management for the distribution of regulatory T cells known as Tregs.

The evo® Cold Chain 2.0 system was chosen in a rigorous evaluation process to determine the best method for temperature regulation and logistics visibility of high-value shipments of source material. 

Bruce McCormick, President of SAVSU, stated, "We are honored that the Diabetes Center and the Department of Surgery at UCSF have selected our evo Smart Shipper technologies. We specifically designed the evo Smart Shipper to improve cold chain logistics and transport survival of small payload cellular therapies such as Tregs."

In an announcement, Jeffrey Bluestone, Ph.D.. the A.W. and Mary Margaret Clausen Distinguished Professor of Metabolism and Endocrinology and Director of the Hormone Research Institute in the Diabetes Center, commented, "Tregs hold great promise as treatments for autoimmune diseases such as diabetes, rheumatoid arthritis and lupus, and even as therapies for cardiovascular disease, neurological diseases and obesity. Effective cold chain management is an important potential component for commercial distribution of these novel cell-based therapies if approved."

Savsu recognizes both the importance and the special challenges of early phase trials and have designed our “evo Phase 1”program to support leading research institutions such as UCSF while significantly reducing operational risk.

For more information about our evo Phase1 program please contact us.


Kite Nabs First Adult CAR-T Approval


"...remarkable recoveries from desperate cases of cancer have led to early approval..."

Really great company doing really great things.    Congrats to everyone at Kite!

We are living in remarkable times.

Read article about the approval at Xconomy here

Dude Where is My CAR-T?

biopharma reporter logo.png

Ravi Nalliah, CEO at TrakCel talks about the new era of "personalized logistics" in this article in BioPharma Reporter.

Note: see our April Blog entry about our collaboration with TrakCel here

Dude where’s my CAR-T? Personalised meds need personalised logistics, says TrakCel

By Dan Stanton+, 01-Sep-2017

After receiving approval Kymriah, Novartis must prove it can handle the supply chain complexities of manufacturing high-value and time-sensitive CAR-T cell therapies, says logistics firm TrakCel.

trakcel logo.jpg

BBC: Zika virus used to treat aggressive brain cancer

 Getty image from BBC post

Getty image from BBC post

Fascinating article on using Zika virus to fight brain cancer.

"It looks like there's a silver lining to Zika."

"latest research shows the virus can selectively infect and kill hard-to-treat cancerous cells in adult brains....Zika injections shrank aggressive tumours in fully grown mice, yet left other brain cells unscathed."

Article posted on  BBC website (read post here), from a report in the Journal of Experimental Medicine

Nanoparticles and Gene Therapy @ The Hutch

fred hutch logo.png

Scientists seeking a simple and gentle way to provide short-term gene therapy have a new tool: nanoparticles. In a paper published August 30 in Nature Communications, Dr. Matthias Stephan at Fred Hutchinson Cancer Research Center describes nanoparticles he has developed that can streamline the delivery of bundled genetic material to specific cells.

“What we’re doing is ‘hit-and-run’ gene therapy,” a strategy in which a brief change to certain cells can have a permanent therapeutic effect, said Stephan, an immunobioengineer who led the study.

Currently, scientists pursuing gene therapy must choose either targeted approaches that permanently alter cells’ DNA, or short-term approaches that are damaging to cells and can’t be restricted to a particular cell type. Now there is a third option.

The nanoparticles’ ability to gently and temporarily provide gene-editing proteins to specific cells is “really the key” that makes the new approach stand out...

 The nanoparticles are formed by bundling synthetic messenger RNA (modified to be safer and more stable than natural RNA) into miniscule packages surrounded by a biodegradable coat. The coat itself is studded with molecules that help the nanoparticles home in on exactly the right cell type.

The researchers showed that hours after the nanoparticles are taken up by target cells, the cells begin churning out proteins based on the new messenger RNA they’ve received. Then, within days, production ceases as the messenger RNA degrades.

Read the full Fred Hutchinson Cancer Research Center article here.

Historic Day!

fda logo.jpg

 FDA announcement on approval of Kymriah CAR T therapy from Novartis.    Historic announcement:  First gene therapy to be approved in the US.  FDA announcement:  read here

"The safety and efficacy of Kymriah were demonstrated in one multicenter clinical trial of 63 pediatric and young adult patients with relapsed or refractory B-cell precursor ALL. The overall remission rate within three months of treatment was 83 percent."

And from Novartis' announcement:

"This therapy is a significant step forward in individualized cancer treatment that may have a tremendous impact on patients' lives," said Carl June, MD, the Richard W. Vague Professor of Immunotherapy, Director of the Center for Cellular Immunotherapies in Penn's Perelman School of Medicine, who is a pioneer of this new treatment. 


Note:  my August 30 original post had a mistake in it.   I referenced a section in the FDA announcement that referred to Actemra instead of Kymriah.   I have corrected the post.

Intriguing data with Juno's new CAR-T therapy

juno logo.png

These new therapies continue to amaze...

Article here

"CAR-T developer Juno Therapeutics has reported data suggesting the benefits of this type of cancer immunotherapy could extend long after the treatment is delivered."

"...the case study 'shows the ability of anti-CD19 CAR-T cells to re-expand in vivo months after the initial CAR T-cell infusion and to re-exert antitumor activity' "

"The big question now is why the CAR-T cells re-activated. The researchers suggest that it may have been a result of the biopsy procedure itself, triggering the response when the presence of the tumour on its own was not sufficient."

Increase Control, Reduce Costs?

fisher bio logo.png

When on message boards we have all read the familiar phrase “don’t hijack this thread” which means don’t stray off topic.   With this post, I am dangerously close to doing that.  So, first let me point you to a new post and white paper offered by Simon Ellison at Fisher Bioservices called “Controlling Complexity [Not Cost] of Advanced Therapy Supply Chain”.   You can visit that page here.  Read it and digest it.   There, I have done my part…now on to the hijacking.

In reading that post, I came across three phrases which combine to support a very similar point that we have been making to decision makers about switching to our evo Cold Chain 2.0 system.  Adopting our evo system increases your CONTROL of your supply chain.  Simon makes the very important point that costs are reduced by increasing control:

…if therapy developers can reduce complexity, they can reduce cost

…complexity is driven by the fact that the therapeutic product is moving between organizations and every movement, although mitigated by SOPs, is a change of location, and personnel.

…complexity is reduced when there is control over chain of custody transactions. 

This may be a bit non-intuitive as control is usually a function of effort (labor hours and activity) which suggests that increasing control inevitably results in higher cost.   However, in the era of “always on”, connected devices this traditional assumption is wrong.   Higher control reduces costs because of the incredibly low, incremental cost of monitoring and communication when it is automated.  [note: there is no “free lunch” and the up-front cost of developing the evo technology and building the software that keeps it running was substantial but, the result is a very low incremental cost per shipment for the user].  

High control/high communication in the evo system results in the production of actionable data and lower losses.  Once configured, the evo system automatically handles communication to all important parties so, labor cost is reduced while decision making quality is increased. delivers location data plus, alarms when packages are opened.   Using fully integrated shippers (integrated through our API) allows monitoring of courier actions throughout the trip.   All of these capabilties increase shipper control and reduce labor costs.

The evo system further increases control by eliminating dependence on remote sites because there are no buttons to push to start cooling or data recording.   evo is always on and always recording.  Outstanding autonomy allows for “3 Pier” shipments with no interim actions or recharge by remote sites.   These features increase your control and decrease costs by eliminating losses and mistakes.

evo Cold Chain 2.0 is a highly integrated SYSTEM made up of advanced technologies that combine to increase CONTROL for therapy developers and DECREASE COSTS arising from compliance, loss, and coordination.  

Fighting Tumors With Gold!

gold nano stars.png

Very interesting article about combining gold nano stars with immunotherapy.

"The nanostar spikes work like lightning rods, concentrating the electromagnetic energy at their tips,"

"When a tumor dies, it releases particles that trigger the immune system to attack the remnants," said Vo-Dinh. "By destroying the primary tumor, we activated the immune system against the remaining cancerous cells, and the immunotherapy prevented them from hiding."

Read more at:

Another interesting 2016 article ("Exploding nanobubbles can kill cancer cells") in Science Magazine about using gold nanoparticles:  here

As hoped, this prevented the heat from spreading to surrounding normal tissues. But the approach had an even more important effect: It caused temperatures to rise higher where there were large clusters of gold nanoparticles. This vaporized adjacent water molecules, creating tiny bubbles that quickly expand and burst, ripping apart the cancer cells. They key, Lapotko says, is that “nanoparticle clusters produce nanobubbles in cancer cells and not normal tissue.”

SAVSU in the news: "Pharma’s cold chain is going below zero"

Cellular and genetic therapies drive a ‘new paradigm’ for logistics

Very good article highlighting the challenges of moving the new cell therapies and industry's response.   Savsu, Bruce McCormick, and our DV-10 featured in the article along with folks from BioLife, TrakCel, Fisher BioServices, and Cryoport.    Thanks to Pharmaceutical Commerce for presenting such a good article and including us.

"While all of this is generating high enthusiasm in R&D circles, logistics service providers are scrambling to revise their processes to meet the new demands of these therapies. A “new paradigm” is evolving, in the words of Bruce McCormick, President of Savsu..."


Way To Go! First Approved Cell and Gene Therapy for Osteoarthritis

The use of pre formulated hypothermic storage and cryogenic freeze media is becoming the cell therapy standard practice. BioLife Solutions is the scientific leader in this field. The ability to store and freeze cells to achieve maximum post thaw viability is a critical process leading to successful cell therapy commercialization. This news represents one more important step forward in bringing the advances of cell therapies into practical commercial application. Congratulations to our friends at Biolife Solutions!